10.1038/nrdp.2016.43 150 Stunda-ZujevaA.BereleM.LeceA.estersA
Verdict at a Glance Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss
Expect and request a real discussion of your medical history, current medications, prior weight-loss attempts, and personal goals before any product changes hands
7 : 147154 Terwel D, Prickaerts J, Meng F, Jolles J
Epidemiology of type 2 diabetesGlobal burden of disease and forecasted trends
Enhancements in Post-Marketing Surveillance: The company has ramped up its post-marketing surveillance efforts, investing in pharmacovigilance to monitor Ozempic use more closely for adverse events